A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

According to a new study, ketamine use has risen significantly since 2015. The results highlight the need for closer monitoring of recreational ketamine use. A recent study analyzing data from the ...

In 2019, the U.S. Food and Drug Administration (FDA) approved the use of a nasal spray ketamine derivative called esketamine (Spravato) to treat depression in adults, according to the National ...

HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...

To overcome some of the pitfalls with dexmedetomidine as the sole agent, there are an increasing number of reports regarding its combination with ketamine. This article provides a descriptive ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

Koruk et al 17 Prospective randomized trial comparing dexmedetomidine–ketamine with midazolam-ketamine in 50 pediatric patients for extracorporeal shock wave lithotripsy Sedation was equally ...